## IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

In re Application of:		
Stephe	en Lloyd MICHELL, et al.	)
International Application No.	PCT/GB2004/001264	) ) )
International Filing Date:	24 March 2004 (24.03.2004)	) )
U.S. Serial No.	10/550,773	
U.S. Filing Date:	27 September 2005 (27.09.2005)	) ) )
For: FRANCISE VACCINE	LLA STRAIN FOR LIVE	) )
Mail Stop PCT Commissioner of Pate	ents	Attorney Docket No. 41577/321208 Date: July 20, 2006

## INFORMATION DISCLOSURE STATEMENT

Sir:

P. O. Box 1450

Alexandria, Virginia 22313-1450

In accordance with Rules 56, 97 and 98 of the Rules of Practice in Patent Cases (37 C.F.R. §§ 1.56, 1.97, and 1.98), the publications listed on the enclosed Form PTO/SB/08 are cited for consideration by the Examiner.

Submission of the references provided in this Information Disclosure is not intended to constitute an admission that any reference referred to herein is prior art for this invention unless specially designated as such. Also, in accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists.

2090057

U.S. Patent Application Serial No. 10/550,773

Filed: 27 September 2005

INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement is being filed pursuant to 37 C.F.R. 1.97(b), before the mailing date of an office action on the merits. Applicant believes that no fee is due for consideration of this paper. However, if a fee is due, the Commissioner is authorized to charge any fee due to Deposit Account No. 11-0855.

Respectfully submitted,

Dean W. Russell

Registration No. 33,452

Dan W Kunn

KILPATRICK STOCKTON LLP Suite 2800, 1100 Peachtree Street Atlanta, Georgia 30309-4530 Phone (404) 815-6528

Approved for use through 10/31/2,9/002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE					Complete if Known				
				Application Number		10/55	10/550,773		
STATEMENT BY APPLICANT					Filing Date		27 September 2005		
					First Named Inventor		Stephen Lloyd MITCHELL		
					Group Art	Unit			
	(use as r	many sheets as	necessary)		Examiner	Name			
Sheet	1	of	1		Attorney D	ocket Number	4157	7/321208	
				U.S. PA	TENT DO	CUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Document	Number	Publica	ation Date	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant	
		Number - Kind Co	de <sup>2</sup> (if known)	MM-D	D-YYYY			Passages or Relevant Figures Appear	
		US 2001/00	24653 A1	09-27-20	001	Gicquel, et al	•		
		US 6,350,45	54 B1	02-26-20	002	Thune			
			N	ION PATENT	LITERATUR	E DOCUMENTS			
Examiner Initials *	Cite No.1		ook, magazi	ne, journal,	serial, symp	•	tc.), date	hen appropriate), title of , page(s), volume-issue shed.	T <sup>2</sup>
	Drabick, et al., 'Analysis of Active Live Immunization Versus Passive Humoral Immunotherapy Against Attenuated and Virulent Strains of Francisella tularensis,' Vaccine Research, 6(2):67-74 (1997)								
			•					nurium Strains to Elicit y, 66(2):732-740 (1998)	

Ellis, et al., 'Tularemia,' Clinical Microbiology Reviews, 631-646 (2002)

FEMS Microbiology Letters, 215:53-56 (2002)

11(3):118-123 (2003)

Microbial & Comparative Genomics, 5(1):25-39 (2000)

Examiner Signature	Date Considered	

Sandstrom, 'The Tularaemia Vaccine,' J. Chem. Tech. Biotechnol., 59:315-320 (1994)

Gray, et al., 'The identification of five genetic loci of Francisella novicida associated with intracellular growth,'

Karlsson, et al., 'Sequencing of the Francisella tularensis Strain Schu 4 Genome Reveals the Shikimate and Purine Metabolic Pathways, Targets for the Construction of a Rationally Attenuated Auxotrophic Vaccine,'

Titball, et al., 'Will the enigma of Francisella tularensis virulence soon be resolved?', TRENDS in Microbiology,

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.